Head-to-head · free

Cyclerion Therapeutics vs Eli Lilly

KRSA vs LLY — return on capital, cash generation, margins and balance sheet side by side.

KRSA

0 / 4

measures where KRSA leads

LLY

4 / 4

measures where LLY leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureKRSA · FY2025LLY · FY2025
Revenue$2.1M$65.2B
Net income(3.5M)$20.6B
Revenue growth (yearly, multi-year)-19.3%23.2%
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC—36.1%
Return on equity—101.4%
Gross margin—83.0%
Operating margin—45.6%
Net debt / EBITDA4.13x1.25x

Figures are as reported by each company; latest fiscal year shown.

Where Cyclerion Therapeutics's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full KRSA profile →

Where Eli Lilly's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full LLY profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons